Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 2
2008 2
2009 5
2010 3
2011 6
2012 3
2013 9
2014 13
2015 11
2016 6
2017 9
2018 8
2019 11
2020 13
2021 9
2022 16
2023 19
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

135 results

Results by year

Filters applied: . Clear all
Page 1
Multiomic landscape of immune pathogenesis in Kimura's disease.
Wu X, Wang A, Zhang S, Wang X, Guo D, Zhu W, Jiao Y, Zhou J, Zhang W, Peng L, Duan M, Fei Y. Wu X, et al. Among authors: duan m. iScience. 2023 Apr 1;26(4):106559. doi: 10.1016/j.isci.2023.106559. eCollection 2023 Apr 21. iScience. 2023. PMID: 37123228 Free PMC article.
Patient-Reported Outcomes in Young Adults with Myeloproliferative Neoplasms.
Bao M, Zhang M, Shi H, Liu X, Duan M, Zhuang J, Du X, Qin L, Hui W, Liang R, Wang M, Chen Y, Li D, Yang W, Tang G, Zhang W, Kuang X, Su W, Han Y, Chen L, Xu J, Liu Z, Huang J, Zhao C, Tong H, Hu J, Chen C, Chen X, Xiao Z, Jiang Q. Bao M, et al. Among authors: duan m. Acta Haematol. 2023;146(4):293-306. doi: 10.1159/000529750. Epub 2023 Feb 22. Acta Haematol. 2023. PMID: 36812897
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study.
Zhang Y, Zhou H, Duan M, Gao S, He G, Jing H, Li J, Ma L, Zhu H, Chang C, Du X, Hong M, Li X, Liu Q, Wang W, Xu N, Yang H, Lu B, Yin H, Wu L, Suo S, Zhao Q, Xiao Z, Jin J. Zhang Y, et al. Among authors: duan m. Am J Hematol. 2023 Oct;98(10):1588-1597. doi: 10.1002/ajh.27033. Epub 2023 Jul 20. Am J Hematol. 2023. PMID: 37470365 Clinical Trial.
Responsive Liquid Metal Droplets: From Bulk to Nano.
Duan M, Zhu X, Shan X, Wang H, Chen S, Liu J. Duan M, et al. Nanomaterials (Basel). 2022 Apr 10;12(8):1289. doi: 10.3390/nano12081289. Nanomaterials (Basel). 2022. PMID: 35457997 Free PMC article. Review.
Shading-based absolute phase unwrapping.
Hu Y, Duan M, Jin Y, Zhu C, Chen E, Xu C. Hu Y, et al. Among authors: duan m. Opt Lett. 2021 Apr 15;46(8):1955-1958. doi: 10.1364/OL.419366. Opt Lett. 2021. PMID: 33857115
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera.
Jin J, Zhang L, Qin A, Wu D, Shao Z, Bai J, Chen S, Duan M, Zhou H, Xu N, Zhang S, Zuo X, Du X, Wang L, Li P, Zhang X, Li Y, Zhang J, Wang W, Shen W, Zagrijtschuk O, Urbanski R, Sato T, Xiao Z. Jin J, et al. Among authors: duan m. Exp Hematol Oncol. 2023 Jun 21;12(1):55. doi: 10.1186/s40164-023-00415-0. Exp Hematol Oncol. 2023. PMID: 37344895 Free PMC article.
135 results